Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zagotenemab First-in-Human Study
NCT02754830Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2016
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zagotenemab in Alzheimer's disease (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) to be Related to Study Drug Administration. Started Apr 2016; status: completed.
02
Drugs
zagotenemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02754830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754830.